Revance Therapeutics (NASDAQ:RVNC) Now Covered by Analysts at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a research report issued on Sunday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

RVNC has been the subject of a number of other reports. HC Wainwright reaffirmed a “neutral” rating and set a $6.60 price target on shares of Revance Therapeutics in a research note on Friday, November 8th. Barclays decreased their price target on Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating for the company in a research note on Monday, December 23rd. Mizuho decreased their price target on Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating for the company in a research note on Tuesday, December 10th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Revance Therapeutics in a research report on Friday, January 17th. Nine investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $8.39.

Revance Therapeutics Stock Performance

Shares of NASDAQ RVNC opened at $3.65 on Friday. The stock has a fifty day moving average price of $3.48 and a two-hundred day moving average price of $4.55. The firm has a market cap of $381.02 million, a P/E ratio of -1.89 and a beta of 0.90. Revance Therapeutics has a 1 year low of $2.30 and a 1 year high of $7.56.

Institutional Investors Weigh In On Revance Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Natixis acquired a new stake in shares of Revance Therapeutics during the 4th quarter valued at $31,000. Two Sigma Securities LLC purchased a new stake in shares of Revance Therapeutics in the fourth quarter valued at $35,000. Alpine Global Management LLC purchased a new stake in shares of Revance Therapeutics in the fourth quarter valued at $37,000. FORA Capital LLC purchased a new stake in shares of Revance Therapeutics in the third quarter valued at $54,000. Finally, RPO LLC purchased a new stake in shares of Revance Therapeutics in the fourth quarter valued at $55,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.